Latest Alligator Bioscience News & Updates

See the latest news and media coverage for Alligator Bioscience. We track all announcements, press releases, and industry mentions in real time, all in one place.

Alligator Bioscience

Clinical-stage biotechnology company developing tumor-directed cancer immunotherapies

alligatorbioscience.se

Headquarters: Lund, Sweden
Founded year: 2001
Company type: Public company
Number of employees: 25–50

Last updated Today

Latest news about Alligator Bioscience

In short: Alligator Bioscience advanced its clinical pipeline, highlighted by the progression of HLX22 into Phase 3 and mitazalimab's readiness for Phase 3.

Company announcements

June 8 Alligator Bioscience

Alligator Bioscience comments on phase 3 trial of HLX22

The first patients have been dosed in all regions globally, marking progress and potential future revenue.

May 8 Alligator Bioscience

Alligator Bioscience welcomes two new board members

Joerg Moeller and Anna Törner bring biotech and governance expertise and join as Alligator advances mitazalimab, a Phase 3‑ready antibody for metastatic pancreatic cancer.

May 6 Alligator Bioscience

Alligator Bioscience holds annual general meeting

Resolutions adopt accounts, discharge board and CEO, elect new board members including Hans-Peter Ostler as Chairman, re-elect PwC as auditor, approve remuneration report, and authorize share issues.

May 5 Alligator Bioscience

Alligator Bioscience releases Q1 2026 report

CEO and CFO present it in a webinar today at 1 p.m. CEST with Q&A.

Media coverage

June 8 The Globe and Mail

Alligator Bioscience Sees Revenue Upside as HLX22 Global Phase 3 Reaches Key Milestone

Alligator Bioscience AB ( (SE:ATORX)) just unveiled an announcement. Alligator Bioscience highlighted progress in a global Phase 3 trial of HLX22, an innovative anti-HER2 monoclonal...

May 6 The Globe and Mail

Alligator Bioscience AGM Backs Loss Carryforward and Expands Capital-Raising Mandate

Alligator Bioscience AB is a Sweden-based biotechnology company headquartered in Lund, focusing on developing innovative immuno-oncology therapies. The company operates in the biopharmaceutical sector, targeting...

May 5 Yahoo Finance

Alligator Bioscience AB Reports Financial Results for The Period 1 January - 31 March 2026 and Provides a Business Update

Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data accepted for AACR 2026. External portfolio progress: The first patient was dosed...

May 5 Dagens industri

Alligator improves the result: "Support for additional long-term value potential"

The research company Alligator Bioscience reports an operating result of -17.8 million kronor (-43.7) for the first quarter of 2026.

Never miss news about Alligator Bioscience

Track Alligator Bioscience and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Alligator Bioscience competitors & trending companies

Browse news for competitors to Alligator Bioscience and other trending companies.